HI-GREAT GROUP HOLDING COMPANY
0.1200+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · HIGR · USD
Key Stats
Market Cap
12.30MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Hi-Great Group Holding reported Q2 FY2025 sales of $10,135, down 33.7% y/y from $15,280, while six-month revenue fell 21.8% y/y to $19,018 amid its development-stage pivot to KRAS gene licensing and herbal supplements. Gross profit shrank to $5,531 in the quarter from $7,380 y/y, with operating expenses trimming to $22,575 from $26,743, yielding a narrower operating loss of $17,044 versus $19,363. Net loss matched the operating figure at $17,044, as minor other income offset interest; YTD net loss widened 25.3% y/y to $35,982 on higher professional fees and G&A. Cash dwindled to $222 by quarter-end from $2,140 at year-start, with operating cash use of $10,871 YTD versus $5,347 generated prior year, and stockholders' deficit deepened to $196,710. No non-GAAP metrics disclosed in the 10-Q. Ongoing COVID-19 disruptions pose a lingering threat to operations.
10-Q
Q1 FY2025 results
Hi-Great Group Holding dipped slightly in Q1 FY2025, with sales at $8,883, down 1.8% y/y from $9,050, while gross profit shrank to $1,382 from $4,178 due to higher royalty costs to related party SellaCare. Operating expenses climbed to $20,758 from $14,987, driven by professional fees and G&A, yielding an operating loss of $19,376 versus $10,809 last year; net loss widened to $18,938, with the gap to operating loss under 3% from minor interest income. Cash drained to $207 from $2,140, reflecting $8,387 used in operations, no capex for FCF calculation, and related-party lease obligations settled. No debt burdens, but stockholders' deficit hit $182,166. Development-stage woes persist. COVID-19 lingers as a drag.
10-K
FY2024 results
Hi-Great Group Holding Company posted FY2024 revenue of $69,210, down 37% y/y from $109,491, with gross profit shrinking to $33,968 amid higher royalty costs to related party SellaCare; yet the net loss narrowed to $48,616 from $121,758, thanks to slashed professional fees and G&A. Q4 momentum showed sequential improvement, as operating cash flow turned positive at $16,127 for the year (derived from adjustments including inventory buildup), signaling better liquidity with cash at $2,140 by year-end. Inventory swelled to $76,150, hinting at ramp-up for agritourism and supplements. No dividends or buybacks; related-party lease expires March 2025. Cybersecurity threats loom large, potentially disrupting data management and quarterly operations.
8-K
DTC eligibility approved
Hi-Great Group Holding Company announced on December 12, 2024, that its application to deposit shares with the Depository Trust Company was approved, enabling electronic book-entry deposits. This upgrade allows eligible shareholders to transfer shares digitally for trading, streamlining the process. DTC eligibility boosts liquidity. Yet, shareholders must meet specific criteria to participate.
10-Q
Q3 FY2024 results
Hi-Great Group Holding eked out Q3 sales of $31,370, down 7.6% y/y from $33,950, yet narrowed its operating loss to $5,306 from $24,838 while gross margins held steady around 56%. For the nine months ended September 30, 2024, revenue fell sharply 42% y/y to $55,700 from $95,782, driving a smaller net loss of $28,617 versus $95,555, with the gap between operating and net loss under 5% tied to minor interest expense. Cash edged up to $3,532 on slim operating use of $122, but free cash flow isn't disclosed in the 10-Q. Inventory dropped to $41,520 from $54,090 year-end, signaling tighter stock. Related-party royalties and leases weigh on costs. Development-stage hurdles persist amid COVID uncertainties.
AAGH
America Great Health
0.00+0.00
BHST
BioHarvest Sciences Inc.
9.84-0.14
ESGH
ESG Inc.
5.52+0.25
GWLL
GOLDENWELL BIOTECH INC
6.00+3.30
HAFG
HOLISTIC ASSET FINANCE GROUP CO
0.68+0.00
HAIN
The Hain Celestial Group, Inc.
1.31-0.04
HFFG
HF Foods Group Inc.
2.16-0.04
HLF
Herbalife Ltd.
8.02-0.09
NATR
Nature's Sunshine Products, Inc
13.42-0.43
USNA
USANA Health Sciences, Inc.
19.61-0.72